Journal of Veterinary Internal Medicine, 2026, 40(2), aalag024
https://doi.org/10.1093/jvimsj/aalag024
Original Research | Small Animal Internal Medicine Respiratory

Increased serum antibody responses to *Aspergillus fumigatus* and house dust mite antigens in dogs with idiopathic eosinophilic bronchopneumopathy

Aude Morgane Canonne[1,2,3,*], Frédéric Billen[3], Pauline Loos[4], Céline Maquet[4], Bernard Mignon[4], Dominique Peeters[3], Laurent Gillet[4], Cecile Clercx[3]

[1]IMRB, INSERM, Univ Paris Est Créteil, Créteil 94010, France
[2]IMRB, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort 94700, France
[3]Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium
[4]Department of Infectious Diseases (Veterinary Vaccinology, Veterinary Parasitology and Mycology), Faculty of Veterinary Medicine, University of Liège, Liège 4000, Belgium
*Corresponding author: Aude Morgane Canonne, Unité de Médecine - DEPEAC, Ecole Nationale Vétérinaire d'Alfort, 7 avenue Charles de Gaules, Maisons-Alfort 94700, France (morgane.canonne-guibert@vet-alfort.fr).

Abstract

Background: **Eosinophilic bronchopneumopathy (EBP) in dogs is an idiopathic disease presumably caused by hypersensitivity to causative allergens that remain unidentified. In humans, allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity to *Aspergillus fumigatus* in uncontrolled asthma in patients.**

Hypothesis/Objectives: **Investigate potential implications of *A fumigatus* and other ubiquitous antigens (house dust mites, HDMs) in dogs with EBP compared to healthy dogs and dogs with chronic bronchitis (CB).**

Animals: **Paired serum and bronchoalveolar lavage fluid (BALF) from dogs with EBP or CB and healthy dogs.**

Methods: **Case–control observational study. Quantitative PCR (qPCR) for *A fumigatus* was performed on BALF and *A fumigatus*-specific antibodies were investigated using a validated ELISA on serum and BALF. An ELISA also was performed for HDM-specific antibodies.**

***Results: Aspergillus fumigatus* qPCR was weakly positive in BALF in 2 of 23 EBP dogs and negative in all other dogs. Concentrations of *A fumigatus*-specific immunoglobulin E (IgE) in serum and BALF were very low and did not differ between groups. Concentrations of *A fumigatus*-specific serum immunoglobulin G (IgG) were higher in EBP dogs than in CB dogs and healthy dogs ($P = .01$) but concentrations in BALF were not different. Concentrations of HDM-specific IgG were higher in both serum and BALF in EBP dogs compared with CB dogs ($P = .01$).**

Conclusions and clinical importance: **Higher concentrations of serum IgG for *A fumigatus* and HDM observed in EBP dogs might suggest an IgG-dependent disease. Based on our results, EBP is not mediated by *A fumigatus*-specific IgE.**

Keywords *Aspergillus*, bronchoalveolar lavage fluid, bronchoscopy, chronic bronchitis, ELISA, immunoglobulin

Abbreviations ABPA, allergic bronchopulmonary aspergillosis; BALF, bronchoalveolar lavage fluid; Bb, *Bordetella bronchiseptica*; CB, chronic bronchitis; CD, cluster of differentiation; CSS, clinical severity score; DLA, dog leukocyte antigen; EBP, eosinophilic bronchopneumopathy; HDMs, house-dust mites; HLA, human leukocyte antigen; HRP, horseradish peroxidase; Ig, immunoglobulin; OD, optical density; PBS, phosphate-buffered saline; qPCR, quantitative polymerase chain reaction; Th2, T-helper cell type 2

Introduction

Idiopathic eosinophilic bronchopneumopathy (EBP) in dogs is a chronic and poorly understood inflammatory airway disease characterized by eosinophilic infiltration of the lungs and bronchial mucosa in young to middle-aged adult dogs.[1–3] Diagnosis of EBP relies on compatible clinical signs, such as chronic cough and variable degrees of respiratory distress, as well as findings from diagnostic imaging and bronchoscopy. Confirmation of eosinophilic inflammation is achieved using cytological examination of bronchoalveolar lavage fluid (BALF) or histopathological analysis of bronchial biopsy samples, with exclusion of other potential causes of eosinophilic infiltration in the lower airways such as parasitic diseases.[2,4] Recently, computed tomodensitometry findings have identified severe bronchiectasis and multifocal obstructive accumulation of fluid or tissue in some dogs.[5,6] The underlying cause of EBP in dogs remains unclear. A T-helper cell type 2 (Th2)-dominant immune

Received: November 9, 2024. **Revised:** January 13, 2026. **Accepted:** January 28, 2026
© The Author(s) 2026. Published by Oxford University Press on behalf of the American College of Veterinary Internal Medicine.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

response with increased numbers of $CD4^+$ T-cells has been described,[7,8] suggesting a potential hypersensitivity reaction to airborne antigens, but specific causative allergens have not yet been identified.[4,9] Previous investigations failed to establish a definitive role for *Mycoplasma canis*, *Mycoplasma cynos*, or *Bordetella bronchiseptica* in triggering or exacerbation of EBP in dogs.[11] Similarly, *Aspergillus* species were only occasionally identified in mycotic cultures of BALF in EBP affected dogs.[2,12] In both studies, *Aspergillus* was considered a contaminant or incidental finding rather than a causative factor.

In humans, eosinophilic bronchial and pulmonary diseases are a heterogeneous group of conditions characterized by substantial eosinophilic infiltration of the bronchi, pulmonary interstitium, alveoli, or some combination of these.[13–21] Among eosinophilic lung diseases, allergic bronchopulmonary aspergillosis (ABPA) is a rare lung disorder resulting from Th2 $CD4^+$ T-cell-mediated hypersensitivity to *Aspergillus fumigatus* antigens in non-immunocompromised patients having a history of asthma or cystic fibrosis. It is characterized by recurrent exacerbation of cough and breathlessness, chronic bronchial obstruction, and development of pathognomonic central cylindrical bronchiectasis with high-attenuation mucous impaction.[15,17,22,23] A definitive diagnosis of ABPA requires increased serum concentrations of *Aspergillus*-specific IgE and increased total IgE in patients with asthma or cystic fibrosis. Additional diagnostic criteria include increased serum concentrations of *A fumigatus* IgG, radiographic evidence of suggestive lung opacities, and a total blood eosinophil count $>$ 500 cells/mL.[15,17,23–25]

Similarities in immunologic and computed tomography findings between dogs with EBP and humans with ABPA prompted the hypothesis that *A fumigatus* could be a triggering or exacerbating aeroallergen in dogs with EBP. To date, quantification of *A fumigatus* DNA in BALF from dogs with EBP using qPCR has not been conducted. With the exception of limited data presented in abstract form,[26] the presence of *A fumigatus*-specific antibodies in the serum of dogs with EBP has not been investigated.

Our aims were (1) to investigate the quantification of *A fumigatus* DNA in BALF from newly diagnosed, corticosteroid-naïve dogs with EBP using qPCR in comparison with BALF collected from dogs with chronic bronchitis (CB) or healthy dogs, (2) to quantitatively evaluate *A fumigatus*-specific IgE and IgG by ELISA testing in serum and BALF from dogs with EBP in comparison with serum and BALF samples from dogs with CB and healthy dogs, and (3) to assess the immune response to another ubiquitous antigen (house dust mites [HDM] antigens) in dogs with EBP and dogs with CB.

Materials and methods

Study design

Case–control observational study.

EBP dogs

Client-owned dogs presented at the Veterinary Small Animal Teaching Hospital of the University of Liege between 2009 and 2016 with newly diagnosed and corticosteroid-naive EBP were retrospectively searched in the medical record database. To be included, EBP dogs had to have (1) a complete medical record regarding clinical history, physical examination findings, and tests results (blood tests, diagnostic imaging, bronchoscopy, and bronchoalveolar lavage analysis), and (2) stored serum and BALF samples had to be available. Dogs with incomplete medical records, missing serum or BALF samples, or those that had previously been treated with corticosteroids were excluded.

Definitive diagnosis of idiopathic EBP was made in accordance with criteria previously described.[2] Briefly, the diagnosis was based on compatible respiratory findings, radiographic changes, bronchoscopic findings, analysis of BALF including bacterial culture, and cytological examination and, in some cases, histopathological examination of endoscopically obtained bronchial mucosal biopsy samples. Exclusion of other causes of eosinophilic airway inflammation, including cardiopulmonary parasites, was required to definitively diagnose idiopathic EBP by using fecal analysis by the Baermann method, BALF analysis (cytology and qPCR for *Angiostrongylus vasorum* and *Crenosoma vulpis*,[27,28]) or both. In addition, all dogs at the time of diagnosis were treated with anthelmintics (fenbendazole 50 mg/kg q24h PO for 5 days; Panacur ND, Intervet International via MSD Animal Health) while results were pending. Definitive diagnosis also was validated by subsequent clinical improvement with corticosteroid treatment in each dog. In each dog, a clinical severity score (CSS; 1-5/5) was assessed at the time of diagnosis based on severity and frequency of cough and evidence of exercise intolerance or lethargy, as previously described.[11] Cough was scored from 1 to 3/3 depending on frequency and severity; presence of retching or exercise intolerance was accorded 1 additional point. Points obtained from cough scoring, retching, and exercise intolerance were added for a maximum total of 5 points.

Bronchoscopy and BALF collection and processing were performed as described previously.[2] Briefly, dogs were anesthetized using various anesthetic protocols after a 5-minute preoxygenation period. Five to 20 mL aliquots (depending on body weight) of sterile saline (0.9% NaCl solution) were instilled twice into a same bronchus and a third time into a different lung lobe via a flexible pediatric endoscope (Fujinon, Paediatric video-bronchoscope EB-530S), followed by immediate aspiration by gentle automated suction using a suction unit with pressure regulator connected to the suction valve of the bronchoscope. The recovered BALF was immediately processed. Aliquots of BALF were used for semiquantitative bacterial culture (SYNLAB Laboratories, Liège, Belgium) according to methods previously described,[29] for total cell count determination using a hemocytometer as well as for cytospin preparation (centrifugation at 1400 rpm, 197 *g*, for 4 min at 20°C; Thermo Shandon Cytospin 4). A total of 400-600 cells/mL was considered normal. Differential cell count calculations were established by counting 300 cells at high power field using the cytospin preparation; BALF cytology was considered normal if $<$ 12% neutrophils and $<$ 7% eosinophils were present. The remaining recovered BALF was centrifuged at 1300 *g* for 15 min at 4°C. Supernatant and cell pellet were stored separately at −80°C. All of the included EBP dogs had a substantial mucus accumulation in the bronchial lumen as well as bronchial mucosal hyperemia. In some dogs, bronchoscopy identified bronchiectasis, bronchomalacia, or both; none of the dogs had clinically relevant nodular lesions of the bronchial mucosa or radiographically detectable granulomas. For all dogs with EBP, BALF total cell count was $>$ 600 cells/mL, and the percentage of eosinophils was $>$ 25% of nucleated cells.

Control groups

Stored serum and BALF samples collected from dogs with CB and from healthy dogs presented at the Veterinary Small Animal Teaching Hospital of the University of Liege were available from previous studies for which ethical approval had previously been obtained from the University Local Ethical Committee. Bronchoscopy, BALF procedure and laboratory processing and storage had been performed as for dogs with EBP.

Diagnosis of CB was made in accordance with previously described criteria.[30] Briefly, diagnosis was based on compatible respiratory clinical complaints (eg, chronic cough for a least 2 months), radiographic changes, bronchoscopy findings, analysis of the BALF including culture, and cytological examination with $>12\%$ neutrophils. For this group of dogs, bacterial origin of neutrophilic airway inflammation was excluded based on cytology (lack of degenerative neutrophils, absence of intracellular bacteria), and quantitative culture and PCR for *B bronchiseptica*. Positive response to inhaled or orally administered corticosteroids also was needed for inclusion. Dogs were excluded if (1) results of any of the required tests were unavailable, (2) if bacterial culture, PCR, or both was positive, or (3) if stored serum and BALF samples were missing.

Dogs with no history or clinical signs of respiratory problems, normal CBC results and for which stored serum and BALF were available were included in the group of healthy control dogs.

qPCR analysis on BALF

Quantification of *A fumigatus* and *Aspergillus* spp. DNA was performed a posteriori on stored BALF from dogs with EBP, dogs with CB and healthy dogs (VPG Exeter [formerly TDDS], United Kingdom). The frozen pelleted cells were thawed and, after resuspension in a small volume of sterile saline (0.9% NaCl solution), samples were sent to the laboratory for qPCR analysis, following the same method as previously described.[10] The qPCR results were expressed as cycle threshold (Ct). The Ct values were arbitrarily further categorized into 5 groups, as previously described[10,11]: very high load ($Ct < 20$), high load (20.1-24), moderate load (24.1-28), low load (Ct 28.1-32), and very low load (>32.1).

Serologic testing for *A fumigatus* in serum and BALF

Because commercially available serologic tests for *A fumigatus*-specific IgG may lack sensitivity and no rigorously validated serologic test is available for *A fumigatus*-specific IgE, an ELISA was developed to assess *A fumigatus*-specific IgG and IgE.

An ELISA was designed in the laboratory to measure *A fumigatus*-specific IgG and IgE in serum and BALF. Archived paired sera and BALF from dogs with EBP, dogs with CB, and healthy dogs were used for ELISA testing.

A pure culture of *A fumigatus* on Sabouraud dextrose agar was obtained from a nasal sample of a dog with sinonasal aspergillosis. The culture was incubated at 37°C for 5-7 days until abundant sporulation was achieved.

The fungal biomass then was harvested by gently scraping the surface of the agar plates using sterile phosphate-buffered saline (PBS). The collected material was transferred into sterile tubes and washed 3 times with PBS to remove residual medium.

Protein (antigen) extraction was performed by suspending the washed fungal biomass in lysis buffer (PBS supplemented with protease inhibitors), followed by mechanical disruption using a bead-beating system (ie, 0.5 mm glass beads, 3 cycles of 1 min at high speed, with cooling on ice between cycles). The lysate was centrifuged at $10\,000 \times g$ for 20 min at 4°C to remove cellular debris, and the supernatant containing soluble antigens was collected and filtered through a 0.22 μm membrane to ensure sterility. The extracted protein was aliquoted and stored at −20°C until use for ELISA plate coating (solution A).

BalBC-mice were intraperitoneally and subcutaneously immunized with the final and pure solution containing *A fumigatus* antigens (solution A) (Ethic Committee agreement N°: LA1610008, University of Liege, Belgium). For 3 mice, alum adjuvant was added to solution A to specifically promote production of specific IgE as previously described.[31] In 3 other mice, Freund's adjuvant was used to specifically promote production of specific IgG.[31] Four control mice that received saline injections with adjuvants also were included. Boosters were injected 2 and 4 weeks after the first administration. Six weeks after the first immunization, mice were euthanized and sera were collected. An ELISA confirmed the presence of *A fumigatus*-specific IgG and IgE in sera of immunized mice. Briefly, ELISA plates were coated with the pure solution of *A fumigatus* antigens (solution A). Sera of mice then were incubated and secondary anti-mouse antibodies were used to detect specific IgG and IgE (ThermoFisher Scientific Waltham, Massachusetts, United States).

Because the ELISA successfully detected *A fumigatus*-specific antibodies in mice, solution A then was used for coating ELISA plates and to test for the presence of *A fumigatus*-specific IgG and IgE in sera and BALF collected from the dogs. Briefly, sera and BALF of dogs with EBP, dogs with CB, and healthy dogs were tested in the same manner for IgG and IgE. For this purpose, sera were incubated on ELISA plates previously coated at 4°C overnight with solution A (100 mL per well) and then a goat anti-dog IgE antibody (horseradish peroxidase [HRP]-conjugated, ThermoFisher) or a goat anti-dog IgG antibody (biotin-conjugated, ThermoFisher) were used.

After coating, plates were washed 3 times with PBS containing 0.05% Tween-20 and blocked with 200 μL of 1% bovine serum albumin in PBS for 1 h at room temperature to prevent nonspecific binding.

After blocking, serum samples were added in duplicate at several dilutions and incubated for 60 min at room temperature. After washing, a goat anti-dog IgE antibody (HRP-conjugated, ThermoFisher) or a goat anti-dog IgG antibody (biotin-conjugated, ThermoFisher) was added at the recommended dilution. All incubation times and conditions for secondary antibodies were performed according to the manufacturer's instructions.

At each step, plates were washed with PBS-T (PBS containing 0.2% Tween 20).

Color development was achieved using 3,3′,5,5′-tetramethylbenzidine substrate, and the reaction was stopped with 2 N H_2SO_4. Optical density (OD) was read at 450 nm using a microplate reader.

Sera of dogs were tested at several dilutions. For IgG, sera were assessed after dilution at 1/30, 1/100, 1/1000, and 1/10 000 for IgE, sera were assessed undiluted and after dilution at 1/30, 1/100, and 1/300. For both IgG and IgE, BALF was tested undiluted and after dilution at 1/100 and 1/1000.

Positive controls for the ELISA consisted of sera from dogs diagnosed with aspergillosis and previously confirmed as seropositive.

To ensure assay specificity, negative controls consisted of blank wells (no serum added) to measure background absorbance and wells without secondary antibody to detect potential nonspecific binding of the detection system.

Intra- and inter-assay variability were assessed using previously characterized serum samples, including both positive and negative controls. For inter-assay precision, all ELISA tests, including samples from EBP dogs, CB dogs, healthy dogs as well as positive and negative controls were reproduced twice for each sample, a few days apart. For intra-essay precision, some ELISA tests were conducted in duplicate using the same plate.

Serologic testing for HDM-specific immunoglobulin G in serum and BALF

Sera and BALF of EBP and CB dogs also were tested for HDM-specific IgG. The ELISA plates were coated with a HDM solution at 4°C overnight (HDM extract, ThermoFisher). Sera and BALF were incubated as described above and a goat anti-dog IgG antibody (biotin-conjugated, ThermoFisher) subsequently was used. Sera were assessed after dilution at 1/1000 and 1/10 000 and BALF was tested undiluted and after dilution at 1/100 and 1/1000.

Statistical analysis

Statistical analyses were performed using commercially available software (GraphPad Prism 9 software).

To compare the proportions of qPCR positive results for *A fumigatus* and *Aspergillus* spp. in BALF between dogs with EBP, CB, and healthy dogs, Fisher's test ($n < 5$) was used. Values of $P \leq .05$ were considered significant.

Optical density (OD) values for IgG and IgE in both sera and BALF were analyzed to determine whether distribution was normal or not. If results were not normally distributed, distributions of OD values would be compared among dogs with EBP, dogs with CB, and healthy dogs using nonparametric tests (Kruskal–Wallis test or Mann–Whitney test). Values of $P \leq .05$ were considered significant.

Given the exploratory nature of our study and the limited sample size inherent to the rarity of EBP, no correction for multiple comparisons was applied. We acknowledge that this approach increases the risk of type I error. Statistical tests were used primarily to identify potential trends to guide future research rather than to confirm hypotheses.

In dogs with EBP, correlation between OD values for *A fumigatus*-specific IgG and HDM-specific IgG was evaluated using Spearman correlation tests at both 1/1000 and 1/10 000 dilutions. Values of $P \leq .05$ were considered significant.

Inter- and intra-assay precision testing were assessed using a paired *t*-test. Values of $P \leq .05$ were considered significant.

Results

qPCR results from BALF

For qPCR testing for *Aspergillus* spp. and *A fumigatus*, stored BALF samples collected from 23 dogs with EBP, 21 dogs with CB, and 14 healthy dogs were retrospectively analyzed (flowchart presented in Figure 1). Of the EBP dogs, 7 were excluded because of missing samples, and 6 because of insufficient serum volume. Twelve CB dogs were excluded for missing samples, and 12 more because of inadequate serum availability. Among the healthy dogs, 4 were excluded because of unavailable serum samples.

Aspergillus spp. qPCR identified a very low load in 2 EBP dogs (Ct = 34 and 33), in 1 dog with CB (Ct = 36), and in 1 healthy dog (Ct = 33), whereas *A fumigatus* qPCR was only positive with a very low load in the same 2 EBP dogs (Ct = 32). Proportions of qPCR positive results were not significantly different between groups. Both the dogs with EBP and detectable *Aspergillus* DNA in their BALF had moderate CSS (3/5) whereas some dogs with negative qPCR results in BALF had more severe clinical signs (CSS, 5/5).

Serologic studies for *Aspergillus*-specific immunoglobulins G and E in serum

For ELISA testing in serum and BALF, 17 dogs with EBP, 9 dogs with CB, and 10 healthy dogs with archived paired serum and BALF were retrospectively evaluated (Figure 1).

Comparative absorbance results for *A fumigatus*-specific IgG in sera from healthy dogs, dogs with CB, and dogs with EBP at 1/30, 1/100, 1/1000, and 1/10 000 dilutions are shown in Figure 2. For all dilutions, absorbance values were significantly higher in dogs with EBP (medians and ranges: 3.5 [2.3-3.7]; 3.1 [1.6-3.7]; 2.1 [1.6-3.5], and 2.0 [0.7-2.7] at 1/30, 1/100, 1/1000, and 1/10 000 dilutions, respectively) compared with dogs with CB (medians and ranges: 2.7 [1.8-3.3]; 2.0 [1.5-2.9]; 1.3 [1.0-1.6], and 0.8 [0.6-1.5] at 1/30 [$P < .0001$], 1/100 [$P < .0001$], 1/1000 [$P < .0001$], and 1/10 000 [$P = .01$] dilutions, respectively). At 1/1000 and 1/10 000 dilutions, absorbance values also were significantly higher in dogs with EBP (medians and ranges: 2.1 [1.6-3.5] and 2.0 [0.7-2.7] at 1/1000 and 1/10 000 dilutions, respectively) compared with healthy dogs (medians and ranges: 1.6 [1.3-1.9] and 1.1 [0.3-1.5] at 1/1000 [$P = .01$] and 1/10 000 [$P = .01$] dilutions, respectively).

Comparative absorbance results for *A fumigatus*-specific IgE in undiluted sera from healthy dogs, dogs with CB, and dogs with EBP are shown in Figure 3 and were not significantly different between groups.

Serologic studies for *Aspergillus*-specific immunoglobulins G and E in BALF

Comparative absorbance results for *A fumigatus*-specific IgG in BALF from healthy dogs, dogs with CB, and dogs with EBP are shown in Figure 4. For undiluted BALF and for the 1/100 dilution, no significant difference was detected between groups. No difference was detected for IgE in undiluted BALF between groups (Figure 4).

Serologic studies for HDM-specific immunoglobulin G in serum and BALF

Comparative absorbance results for HDM-specific IgG in sera and BALF from dogs with CB and dogs with EBP are shown in Figure 5. The ELISA OD values were significantly higher in serum from EBP dogs (medians and ranges: 2.5 [0.3-2.9] and 2.5 [0.6-3.1] at 1/1000 and 1/10 000 dilutions, respectively) compared with serum from CB dogs (medians and ranges: 1.8 [1.2-2.0] and 1.6 [0.3-2.0] at 1/1000 [$P < .0001$] and 1/10 000 [$P = .01$] dilutions, respectively).




Figure 1 Flowchart of inclusion of dogs with idiopathic eosinophilic bronchopneumopathy, dogs with CB, and healthy dogs. Abbreviations: BALF = bronchoalveolar lavage fluid; CB, chronic bronchitis.




Figure 2 ELISA absorbance results for *A fumigatus*-specific Ig G in serum from healthy dogs, dogs with CB, and dogs with EBP at 1/30, 1/100, 1/1000 and 1/10 000 dilutions. For all dilutions, differences were significant between dogs with CB and dogs with EBP. (**: $P = .01$; ***: $P < .001$; ****: $P < .0001$). Abbreviations: CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.

The ELISA OD values also were significantly higher in BALF from EBP dogs (medians and ranges: 0.9 [0.4-2.5] and 0.7 [0.3-2.4] at 1/100 and 1/1000 dilutions, respectively) compared with BALF from CB dogs (medians and ranges: 0.5 [0.4-1.3] and 0.4 [0.3-0.7] at 1/100 [$P = .03$] and 1/1000 [$P = .01$] dilutions, respectively).

Comparison with healthy dogs was not performed.

Correlation between optical density values for *A fumigatus*-specific immunoglobulin G and for HDM-specific immunoglobulin G in EBP dogs

The OD values of serum *A fumigatus*-specific IgG were moderately correlated with serum values of HDM-specific IgG in dogs with EBP at 1/10 000 dilution (Figure 6; $r = 0.51$; $P = .04$). Correlation was not found for 1/1000 dilution.

Inter- and intra-assay precision

Absorbance results obtained in duplicate for IgG in sera from dogs with EBP and dogs with CB are presented in Figure 7 at dilutions 1/1000 and 1/10 000. For 8/9 dogs with CB and each dog with EBP, both values measured with a 1/1000 or 1/10 000 dilution were not significantly different.

Absorbance results obtained in duplicate for IgG in BALF from dogs with EBP and dogs with CB are presented in Figure 8 at dilutions 1/100 and 1/1000. For each dog with CB and each dog with EBP, both values measured in BALF with a 1/100 or 1/1000 dilution were not significantly different.

Figure 9 presents ELISA absorbance results obtained twice, few days apart, for *A fumigatus*-specific IgG in sera from dogs with




Figure 3 ELISA absorbance results for *A fumigatus*-specific Ig E in serum from healthy dogs, dogs with CB, and dogs with EBP for undiluted sera. No significant difference (ns) was detected between groups. Abbreviations: CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.

CB and dogs with EBP at dilutions 1/1000 and 1/10 000. For 8/9 dog with CB and each dog with EBP, both values measured with a 1/1000 or 1/10 000 dilution were not significantly different.

Discussion

Our study represents a comprehensive investigation into the potential implication of *A fumigatus* in the pathogenesis of EBP in dogs. Weak positive qPCR results in BALF from EBP dogs occasionally were observed, but the proportion of positive results did not differ significantly when compared to dogs with CB and healthy dogs. Nevertheless, serum concentrations of *A fumigatus*-specific IgG were higher in EBP dogs compared with CB dogs or healthy dogs, and EBP dogs also had higher concentrations of HDM-specific IgG in both serum and BALF compared to dogs with CB. Finally, concentrations of *A fumigatus*-specific IgE in both serum and BALF were notably low and did not differ significantly between groups.

No significant difference was found in the quantification of *Aspergillus* spp. or *A fumigatus* DNA in BALF among EBP dogs, CB dogs, and healthy dogs. In the EBP dogs that tested positive, the DNA was present in only small amounts and both of the dogs with detectable *Aspergillus* DNA in their BALF had a moderate CSS whereas some dogs with negative qPCR results in BALF had more severe clinical signs. Thus, the presence of *A fumigatus* would not be associated with development or exacerbation of EBP in dogs. The first large case series of dogs with EBP reported positive *Aspergillus* spp. cultures in 2 of 22 dogs.[2] In a more recent study, a single *Aspergillus* colony also was detected in a dog with EBP.[12] For both studies, given the small numbers of dogs with positive *Aspergillus* culture, the authors were unable to draw any conclusions about the causal role of *Aspergillus* in EBP in dogs, and it was instead considered a contaminant or incidental finding. As suggested by these earlier studies, we cannot rule out that the few positive qPCR results observed in BALF from dogs in our study may reflect a similar incidental presence. However, the comparisons among the 3 groups may be underpowered because of the small sample sizes. In humans with ABPA, although positive culture or PCR results from airway samples are not required for definitive diagnosis, studies have shown that PCR is more sensitive when performed on sputum, bronchial, and tracheal samples compared with BALF, likely because of dilution.[32] Nonetheless, the higher probability to detect fungal contaminants in upper respiratory tract samples also is legitimately questionable. Therefore, additional investigation into qPCR performed on more proximal airway samples, such as bronchial or tracheal secretions, might be of interest in dogs with EBP.

Based on previous immunologic studies in dogs with EBP suggesting implication of the Th_2 pathway,[7,8] we would have expected to observe difference in OD values for *Aspergillus*-specific IgE in both sera and BALF between EBP dogs and other dogs. Despite some immunologic and imaging similarities, the absence of detectable *A fumigatus*-specific IgE in dogs with EBP does not support the hypothesis that EBP in dogs is comparable to ABPA in humans. However, our ELISA test might lack sufficient sensitivity. A pure *A fumigatus* culture was used with mechanical disintegration and filtration, as is performed in humans for serologic testing. This technique provides somatic and extracellular antigens, which may be less sensitive. Recent reviews in the human medical literature suggest that serologic assays using recombinant antigens may offer higher sensitivity, although conflicting results have been observed regarding the most suitable recombinant antigen (*Asp f* 1, 2, 3, 4, 6).[25] Among these, recombinant antigens *Asp f* 1 and *Asp f* 2 may have the highest immunogenic potential.[33,34] Thus, complementary serologic assays for IgE in dogs with EBP performed using ELISA plates coated with recombinant and more immunogenic *A fumigatus* antigens could have improved the sensitivity of the serologic assay.

In contrast, significantly higher concentrations of serum *A fumigatus* IgG were detected at several dilutions in dogs with EBP compared with healthy dogs and dogs with CB. In humans, *A fumigatus*-specific IgG is commonly observed in cases of *Aspergillus* bronchitis. Diagnosis of *Aspergillus* bronchitis typically is based on positive culture or PCR results from BALF or sputum[25] whereas specific imaging findings of chronic pulmonary aspergillosis or ABPA are absent. Therefore, EBP in dogs does not resemble *Aspergillus* bronchitis in humans. Furthermore, extrinsic allergic alveolitis or hypersensitivity pneumonitis are other lung diseases in humans that may be associated with increased *A fumigatus*-specific IgG,[32] but they are defined by lymphocytosis in BALF, a feature not found in dogs with EBP.

The OD values for HDM-specific IgG also were significantly higher in both serum and BALF from dogs with EBP compared with samples from dogs with CB. The possibility of cross-reactivity between *A fumigatus* and HDM warrants consideration. The crude fungal extracts used in solution A for coating ELISA plates may contain cross-reactive allergenic proteins (pan-allergens) that could be present in a variety of parasitic species.[35] A recent study identified a specific antigen of HDM, Der f34, which belongs to a highly conserved family of imine deaminases and demonstrates cross-reactivity with *A fumigatus.*[36] In that study, cross-reactivity was not observed with *Alternaria alternata.* Consequently, it would be valuable to assess *A alternata*-specific IgG in dogs with EBP using recombinant antigens from this saprophyte to determine whether the increased HDM antibody concentrations




Figure 4 ELISA absorbance results for *A fumigatus*-specific Ig G in BALF from healthy dogs, dogs with CB, and dogs with EBP in undiluted BALF and for a 1/100 dilution. No significant difference (ns) was detected between groups. (4bis) ELISA absorbance results for *A fumigatus*-specific Ig E in undiluted BALF from healthy dogs, dogs with CB and dogs with EBP. No significant difference (ns) was detected between groups. Abbreviations: BALF = bronchoalveolar lavage fluid; CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.




Figure 5 ELISA absorbance results for HDM-specific Ig G in sera and BALF from dogs with CB and dogs with EBP at 1/1000 and 1/10 000 dilutions for sera and at 1/100 and 1/1000 dilutions for BALF. For all comparisons, differences were significant between dogs with CB and dogs with EBP (*: $P = .03$; **: $P = .01$; ***: $P < .001$; ****: $P < .0001$). Abbreviations: BALF = bronchoalveolar lavage fluid; CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy; HDM = house dust mite.

in serum and BALF of EBP dogs reflect cross-reactivity with *A fumigatus*.

Another possible explanation for the higher OD values observed in EBP dogs for *A fumigatus*-IgG and HDM-IgG is that IgG-mediated hypersensitivity reactions involving several aeroallergens may play a role in dogs with EBP. In humans, *A alternata* and *Candida albicans* are among the most common fungi responsible for allergic bronchopulmonary mycosis induced by fungi other than *A fumigatus*.[35,37,38] Again, additional serologic investigations should be done in dogs with EBP, including specific investigation of Ig G against other fungi as well as other environmental mites, to strengthen our hypothesis.

In people, some genetic risk factors have been identified for the development of ABPA, such as specific human leukocyte antigen (HLA) genotypes or polymorphism in Toll-like receptors. Patients carrying the HLA-DR2 or HLA-DR5 phenotypes are more susceptible to ABPA.[33] Although polymorphisms in dog leukocyte antigen genotypes or Toll-like receptors have not been investigated in dogs with EBP compared to those with CB, our serologic results suggest that EBP in dogs is distinct from ABPA in humans.

The OD values of serum *A fumigatus*-specific IgG were moderately correlated with HDM-specific IgG at a 1/10 000 dilution but not at 1/1000, which could be explained by several factors. The 1/1000 dilution may have led to signal saturation in the ELISA. This possibility could have masked actual correlations between *A fumigatus*-specific IgG and HDM-specific IgG. At 1/10 000, differences in antibody concentrations between dogs became more apparent, allowing for better detection of the correlation. Secondly, at 1/1000, background noise (eg, nonspecific binding, protein interactions) may have been more pronounced, potentially obscuring correlations. At 1/10 000, dilution decreased these unwanted effects, identifying a more clear relationship between *A fumigatus*-specific IgG and HDM-specific IgG.

Our study had several limitations. First, the sample sizes used for the comparisons between groups (EBP dogs, CB dogs, and healthy dogs) were relatively small, which might affect the ability to detect significant differences, particularly for qPCR results. Furthermore, although the analyses of *Aspergillus* DNA in BALF did not show marked differences among groups, this approach




Figure 6 Optical density values for serum *Aspergillus*-specific and HDM-specific Ig G in each dog with EBP at 1/1000 and 1/10 000 dilutions. R: Spearman coefficient. Correlation was significant for 1/10 000 dilution ($r = 0.51$, $P = .04$). Abbreviations: EBP = eosinophilic bronchopneumopathy; HDM = house dust mite.




Figure 7 Intra-assay precision. ELISA absorbance results in duplicate for *A fumigatus*-specific Ig G in serum from dogs with CB and dogs with EBP at 1/1000 and 1/10 000 dilutions. For 8/9 dog with CB and each dog with EBP, both values measured with a 1/1000 or 1/10 000 dilution were nonsignificantly different. Abbreviations: CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.




Figure 8 Intra-assay precision. ELISA absorbance results in duplicate for *A fumigatus*-specific Ig G in BALF from dogs with CB and dogs with EBP at 1/100 and 1/1000 dilutions. For each dog with CB and each dog with EBP, both values measured in BALF with a 1/100 or 1/1000 dilution were nonsignificantly different. Abbreviations: BALF = bronchoalveolar lavage fluid; CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.




Figure 9 Inter-assay precision. ELISA absorbance results in few days apart for *A fumigatus*-specific Ig G in serum from dogs with CB and dogs with EBP at 1/1000 and 1/10 000 dilutions. For 8/9 dog with CB and each dog with EBP, both values measured with a 1/1000 or 1/10 000 dilution were nonsignificantly different. Abbreviations: CB = chronic bronchitis; EBP = eosinophilic bronchopneumopathy.

may be less sensitive, especially because of sample dilution in BALF and the use of somatic and extracellular antigens for the ELISA. On the other hand, detection of *Aspergillus* DNA could be influenced by contaminants from the upper respiratory tract. Moreover, the possibility of cross-reactivity between *A fumigatus* and other environmental allergens, such as HDM, suggests that assessing additional antibodies, including those against other fungal antigens and environmental allergens, would be essential for gaining a deeper understanding of the underlying immunologic mechanisms of EBP. Furthermore, evaluation of HDM antibodies could not be conducted in healthy dogs. Because the ELISA was performed manually rather than using a standardized commercial test, the comparability of our findings with other studies using commercial assays could be limited. Another limitation of our study is the absence of correction for multiple statistical comparisons, which may increase the risk of false-positive results (type I error). However, given the exploratory design and small sample size related to the rarity of EBP, we prioritized sensitivity to detect possible associations over strict control of α error. Our findings are exploratory and should be interpreted with caution and considered as preliminary data to inform and justify future, adequately powered confirmatory studies.

In conclusion, although limited by small sample size and absence of a formal power analysis, we found that dogs with EBP have higher concentrations of serum *A fumigatus* IgG compared with healthy dogs and dogs with CB, but detection of *Aspergillus* DNA in BALF and concentrations of *A fumigatus* IgE in both serum and BALF did not differ between groups. In addition, dogs with EBP had higher concentrations of HDM-IgG in both serum and BALF compared with dogs with CB. These findings suggest that EBP in dogs may be different from ABPA in humans. These exploratory findings offer important insights that may guide the design of future, larger-scale, case–control studies aiming to better understand the role of environmental antigens, including *Aspergillus* and HDM, in the pathogenesis of EBP.

Author contributions

Aude Morgane Canonne (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing—original draft, Writing—review & editing), Frédéric Billen (Conceptualization, Methodology, Supervision), Pauline Loos (Data curation, Formal analysis, Software, Supervision), Céline Maquet (Data curation, Formal analysis, Software, Supervision), Bernard Mignon (Data curation, Supervision), Dominique Peeters (Conceptualization, Supervision, Writing—review & editing), Laurent Gillet (Conceptualization, Data curation, Formal analysis, Supervision), and Cecile Clercx (Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Writing—review & editing)

Conflicts of interest

The authors declare no conflicts of interest.

Funding

The authors received no specific funding for this work.

Off-label antimicrobial declaration

The authors declare no off-label use of antimicrobials.

Institutional animal care and use committee or other approval declaration

Ethics Committee Agreement for University of Liege, number LA1610008.

Human ethics approval declaration

The authors declare human ethics approval was not needed.

References

1. Corcoran BM, Thoday KL, Henfrey JI, Simpson JW, Burnie AG, Mooney CT. Pulmonary infiltration with eosinophils in 14 dogs. *J Small Anim Pract*. 1991;32:494-502. https://doi.org/10.1111/j.1748-5827.1991.tb00863
2. Clercx C, Peeters D, Snaps F, et al. Eosinophilic bronchopneumopathy in dogs. *J Vet Intern Med*. 2000;14:282-291. https://doi.org/10.1892/0891-6640(2000)014<0282:ebid>2.3.co;2
3. Rajamäki MM, Järvinen AK, Sorsa T, Maisi P. Clinical findings, bronchoalveolar lavage fluid cytology and matrix metalloproteinase-2 and -9 in canine pulmonary eosinophilia. *Vet J*. 2002;163:168-181. https://doi.org/10.1053/tvjl.2001.0631
4. Clercx C, Peeters D. Canine eosinophilic bronchopneumopathy. *Vet Clin North Am Small Anim Pract*. 2007;37:917-35, vi. https://doi.org/10.1016/j.cvsm.2007.05.007
5. Meler E, Pressler BM, Heng HG, Baird DK. Diffuse cylindrical bronchiectasis due to eosinophilic bronchopneumopathy in a dog. *Can Vet J*. 2010;51:753-756.
6. Mesquita L, Lam R, Lamb CR, McConnell J. Computed tomographic findings in 15 dogs with eosinophilic bronchopneumopathy. *Vet Radiol Ultrasound*. 2015;56:33-39. https://doi.org/10.1111/vru.12187
7. Peeters D, Clercx C, Day MJ. Distribution of leucocyte subsets in bronchial mucosa from dogs with eosinophilic bronchopneumopathy. *J Comp Pathol*. 2005;133:128-135. https://doi.org/10.1016/j.jcpa.2005.02.004
8. Peeters D, Peters IR, Clercx C, Day MJ. Real-time RT-PCR quantification of mRNA encoding cytokines, CC chemokines and CCR3 in bronchial biopsies from dogs with eosinophilic bronchopneumopathy. *Vet Immunol Immunopathol*. 2006;110:65-77. https://doi.org/10.1016/j.vetimm.2005.09.004
9. Clercx C, Peeters D, German AJ, et al. An immunologic investigation of canine eosinophilic bronchopneumopathy. *J Vet Intern Med*. 2002;16:229-237. https://doi.org/10.1892/0891-6640(2002)016<0229:aiioce>2.3.co;2
10. Biénès T, Vangrinsven E, Fastrès A, Garigliany M-M, Billen F, Clercx C. Utility of fungal polymerase chain reaction on nasal swab samples in the diagnosis and monitoring of sinonasal aspergillosis in dogs. *J Vet Intern Med*. 2022;36:1295-1302. https://doi.org/10.1111/jvim.16441
11. Canonne AM, Peters I, Roels E, Desquilbet L, Clercx C. Detection of specific bacterial agents by quantitative PCR assays in the bronchoalveolar lavage fluid of dogs with eosinophilic bronchopneumopathy vs. dogs with chronic bronchitis and healthy dogs. *Vet J*. 2018a;232:52-56. https://doi.org/10.1016/j.tvjl.2017.12.014
12. Johnson LR, Johnson EG, Hulsebosch SE, Dear JD, Vernau W. Eosinophilic bronchitis, eosinophilic granuloma, and eosinophilic bronchopneumopathy in 75 dogs (2006-2016). *J Vet Intern Med*. 2019;33:2217-2226. https://doi.org/10.1111/jvim.15605
13. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. *Eur Respir Rev*. 2011;20:156-174. https://doi.org/10.1183/09059180.00001011
14. Akuthota P, Weller PF. Eosinophilic pneumonias. *Clin Microbiol Rev*. 2012;25:649-660. https://doi.org/10.1128/CMR.00025-12
15. Agarwal R, Chakrabarti A, Shah A, et al. (ABPA complicating asthma ISHAM working group) allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy*. 2013;43:850-873. https://doi.org/10.1111/cea.12141
16. Cottin V. Eosinophilic lung diseases. *Clin Chest Med*. 2016;37:535-556. https://doi.org/10.1016/j.ccm.2016.04.015
17. Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. *Allergy Asthma Immunol Res*. 2016;8:282-297. https://doi.org/10.4168/aair.2016.8.4.282
18. Lai K, Chen R, Peng W, Zhan W. Non-asthmatic eosinophilic bronchitis and its relationship with asthma. *Pulm Pharmacol Ther*. 2017;47:66-71. https://doi.org/10.1016/j.pupt.2017.07.002
19. Weissler JC. Eosinophilic lung disease. *Am J Med Sci*. 2017;354:339-349. https://doi.org/10.1016/j.amjms.2017.03.020
20. Allen J, Wert M. Eosinophilic pneumonias. *J Allergy Clin Immunol Pract*. 2018;6:1455-1461. https://doi.org/10.1016/j.jaip.2018.03.011

21. Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. *Allergol Int*. 2019;68:413-419. https://doi.org/10.1016/j.alit.2019.05.006
22. Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Diagnosing allergic bronchopulmonary aspergillosis: a review. *Cureus*. 2019;11:e4550. https://doi.org/10.7759/cureus.4550
23. Agarwal R, Sehgal IS, Dhooria S, et al. Allergic bronchopulmonary aspergillosis. *Indian J Med Res*. 2020;151:529-549. https://doi.org/10.4103/ijmr.IJMR_1187_19
24. Agarwal R, Aggarwal AN, Sehgal IS, Dhooria S, Behera D, Chakrabarti A. Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis. *Mycoses*. 2015;58:408-412. https://doi.org/10.1111/myc.12334
25. Page ID, Richardson M, Denning DW. Antibody testing in aspergillosis—quo vadis? *Med Mycol*. 2015;53:417-439. https://doi.org/10.1093/mmy/myv020
26. Peyron C, Derer M, Day MJ, Massart L, Clercx C, Peeters D. Concentration of allergen-specific Ig E in serum and bronchoalveolar lavage fluid in dogs with eosinophilic bronchopneumopathy and dogs with chronic bronchitis. In: *Proceedings of the 19th ECVIM-CA Congress*, Porto, Portugal, 2009:1337.
27. Canonne AM, Roels E, Caron Y, et al. Detection of *Angiostrongylus vasorum* by quantitative PCR in bronchoalveolar lavage fluid in Belgian dogs. *J Small Anim Pract*. 2016;571:130-134. https://doi.org/10.1111/jsap.12419
28. Canonne AM, Billen F, Losson B, Peters I, Schnyder M, Clercx C. Angiostrongylosis in dogs with negative fecal and in-clinic rapid serologic tests: 7 cases (2013-2017). *J Vet Intern Med*. 2018;32:951-955. https://doi.org/10.1111/jvim.15092
29. Peeters D, McKiernan BC, Weisiger RM, Schaeffer DJ, Clercx C. Quantitative bacterial cultures and cytological examination of bronchoalveolar lavage specimens in dogs. *J Vet Intern Med*. 2000;14:534-541. https://doi.org/10.1892/0891-6640(2000)014<0534:qbcace>2.3.co;2
30. Rozanski E. Canine chronic bronchitis. *Vet Clin North Am Small Anim Pract*. 2014;44:107-116. https://doi.org/10.1016/j.cvsm.2013.09.005
31. Beck L, Spiegelberg HL. The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant. *Cell Immunol*. 1989;123:1-8. https://doi.org/10.1016/0008-8749(89)90263-3
32. Denning DW. Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape. *Int J Tuberc Lung Dis*. 2021;25:525-536. https://doi.org/10.5588/ijtld.21.0053
33. Carsin A, Romain T, Ranque S, et al. *Aspergillus fumigatus* in cystic fibrosis: an update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis. *Allergy*. 2017;72:1632-1642. https://doi.org/10.1111/all.13204
34. Alghamdi N, Barton R, Wilcox M, Peckham D. Serum Ig E and IgG reactivity to aspergillus recombinant antigens in patients with cystic fibrosis. *J Med Microbiol*. 2019;68:924-929. https://doi.org/10.1099/jmm.0.000991
35. Fukutomi Y, Tanimoto H, Yasueda H, Taniguchi M. Serological diagnosis of allergic bronchopulmonary mycosis: Progress and challenges. *Allergol Int*. 2016;65:30-36. https://doi.org/10.1016/j.alit.2015.08.004
36. ElRamlawy KG, Fujimura T, Baba K, et al. Der f 34, a novel major house dust mite allergen belonging to a highly conserved rid/YjgF/YER057c/UK114 family of imine deaminases. *J Biol Chem*. 2016;291:21607-21615. https://doi.org/10.1074/jbc.M116.728006
37. Ishiguro T, Takayanagi N, Kagiyama N, Shimizu Y, Yanagisawa T, Sugita Y. Clinical characteristics of biopsy-proven allergic bronchopulmonary mycosis: variety in causative fungi and laboratory findings. *Intern Med*. 2014;53:1407-1411. https://doi.org/10.2169/internalmedicine.53.2230
38. Bush A. Kids, difficult asthma and fungus. *J Fungi*. 2020;6:55. https://doi.org/10.3390/jof6020055

© The Author(s) 2026. Published by Oxford University Press on behalf of the American College of Veterinary Internal Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Journal of Veterinary Internal Medicine, 2026, 40, 1–10
https://doi.org/10.1093/jvimsj/aalag024
Original Research